Heart valve technology to be presented at major conference

The York-based company said that research into dCELL - which allows decellurlarised human heart valves to be used in heart surgery instead of common pulmonary valve substitutes - would be presented at the 7th Biennial Congress of the Society for Heart Valve Disease & Heart Valve Society of America in Venice, Italy, on June 23.

Renowned cardiac surgeon Professor Francisco da Costa, who is based at Pontifical University of Parana, Brazil and is one of the company’s long term clinical collaborators, will present the findings.

Antony Odell, managing director of Tissue Regenix said: “We are pleased to see recognition for dCELL heart valve technology by this internationally distinguished congress. It is an important step towards the company’s commercialisation in this key area.”

Professor Francisco da Costa, research partner of Tissue Regenix said: “In this single institutional study, dCELL allografts have demonstrated superior results when compared to conventional cryopreserved allografts. In our experience, the decellularised valves seem to be providing superior reconstruction in these patients. It has been very gratifying to see such excellent results.”

The study used data from more than 400 patients over an eight-year period and found that patients had a less immunogenic reaction, no calcification, partial re-population of the grafts and there were particularly good results in younger patients.